BASEL, SWITZERLAND--(Marketwire - February 08, 2008) - Basilea Pharmaceutica Ltd. (SWX: BSLN) announces 2007 financial results reflecting the successful advancement of two drug candidates into pre-registration phase and one into phase III development. Combined cash and short-term investments amount to CHF 424.8 million as of December 31, 2007.
